1
Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults
Condition(s):COVID-19Last Updated:May 3, 2023Withdrawn
Phase I II: 12406 Clinical Trials, Page 1 of 1241
Hide Studies Not Open or Pending
2
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies
Condition(s):Epithelial Ovarian Cancer; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Urothelial Carcinoma; Non-Small Cell Lung Cancer; Small-Cell Lung Cancer; Endometrial Carcinoma; Head and Neck Squamous Cell Carcinoma; Breast CancerLast Updated:December 1, 2022Recruiting
3
Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors
Condition(s):NeoplasmsLast Updated:January 3, 2019Unknown status
4
A Phase I-II Study on Stereotactic Body Radiotherapy in 3 Fractions for Low/Int Risk Prostate Cancer
Condition(s):Prostate CancerLast Updated:March 9, 2021Unknown status
5
Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma
Condition(s):Metastatic MelanomaLast Updated:August 29, 2013Completed
6
GFM-Acadesine: A Phase I-II Trial of Acadesine
Condition(s):SMDLast Updated:November 8, 2016Terminated
7
Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)
Condition(s):Lung CancerLast Updated:February 8, 2012Withdrawn
8
Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma
Condition(s):Melanoma BRAF V600E/K Mutated; CDNKN2A Loss DefinedLast Updated:April 18, 2016Unknown status
9
Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis
Condition(s):Relapsing Remitting Multiple Sclerosis (RRMS)Last Updated:December 15, 2016Completed
10
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
Condition(s):Breast Cancer; Breast Cancer, Male; Breast Cancer Female; HER2-positive Breast CancerLast Updated:April 19, 2023Completed